Neurometrix Inc (NURO) Given Consensus Rating of “Hold” by Brokerages
Shares of Neurometrix Inc (NASDAQ:NURO) have been given a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.
Zacks has also assigned Neurometrix an industry rank of 121 out of 255 based on the ratings given to related companies.
Separately, ValuEngine cut Neurometrix from a “buy” rating to a “hold” rating in a research note on Wednesday, April 18th.
Shares of NURO opened at $1.25 on Friday. The stock has a market capitalization of $8.90 million, a P/E ratio of -0.11 and a beta of 0.34. Neurometrix has a 1-year low of $1.11 and a 1-year high of $2.96.
Neurometrix (NASDAQ:NURO) last released its earnings results on Thursday, July 19th. The medical device company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.39. Neurometrix had a negative return on equity of 77.46% and a negative net margin of 27.12%. The company had revenue of $3.75 million for the quarter. analysts expect that Neurometrix will post 0.02 earnings per share for the current fiscal year.
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Recommended Story: How to Invest in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.